Get to know our clinical trials
Betahistine trial in adult patients with Meniere's disease
THE OBJECTIVE OF THE STUDY IS TO EVALUATE THE EFFICACY AND SAFETY OF THE DRUG BETAHISTINE PR 48 MG (EXTENDED RELEASE AND ONCE DAILY).
Codirector
Otorhinolaryngology Department
Madrid headquarters
Status
In recruitment
headquarters
Madrid
Technical Summary
- MULTICENTER, THREE-ARM, DOUBLE-BLIND, DOUBLE-DUMMY, DOUBLE-DUMMY, PARALLEL-GROUP, PLACEBO-CONTROLLED STUDY FOR THE EVALUATION OF THE EFFICACY AND SAFETY OF THE EXTENDED-RELEASE FORMULATION OF BETAHISTIN PR 48 MG ONCE DAILY COMPARED TO THE CONVENTIONAL RELEASE FORMULATION OF BETAHISTIN IR 24 MG, TWICE DAILY IN THE TREATMENT OF ADULT PATIENTS WITH MENIERE'S DISEASE.
- Code EudraCT: 2020-005246-42
- Protocol number: 0796-19
- Promoter: Intas Pharmaceuticals Limited
* The trials only admit a limited number of patients and are subject to inclusion and exclusion criteria. The specialist who assesses your case will inform you of the conditions required to participate in the clinical trial.
More information about this clinical trial
Information offered by the Spanish Registry of Clinical Studies
- Summary
- Information
- Calendar
- Headquarters
- Drugs
Do you want to participate in this trial?
Request an appointment for our specialists to assess whether you qualify for this clinical trial
Do you prefer to send us your reports?
If you prefer, you can send us your medical information and our specialists will evaluate your case without the need to come to the Clinica.